Bristol-Myers Squibb Company (BMY)
This Drugmaker Is Too Cheap to Ignore. Why Bristol Is a Buy.
Bristol Myers Squibb trades at seven times earnings, with multiple growth drivers.
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Why Bristol-Myers Squibb Remains Undervalued In 2025
Bristol-Myers Squibb remains my favorite, almost the only Big Pharma stock that hasn't left the accumulation zone. Sales of its "gem" in the cardiovascular franchise, Camzyos, were $296 million in Q3, up 89.7% year-over-year. On the other hand, my concerns about Opdivo Qvantig did not materialize, as its sales reached $67 million, double the Q2 figures.
BMY Stock Down on Discontinuation of ACS Clinical Study With JNJ
BMY shares drop after halting the Librexia ACS trial, though other milvexian studies continue with top-line data expected in 2026.
BMY's Growth Portfolio Shines in Q3: Turning Point Ahead?
Bristol Myers' strong Q3 growth portfolio, led by Opdivo and Reblozyl, helped counter declines in legacy drug sales.
Here's Why Bristol Myers Squibb (BMY) is a Strong Value Stock
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Bristol Myers Gains 7.2% in a Month: Buy, Sell or Hold the Stock?
Bristol Myers Squibb's strong Q3 driven by soaring demand for Opdivo, Reblozyl, Breyanzi and Camzyos pushes shares up 7.2% in a month.
5 High-Yield Blue-Chip Dividend Giants Set to Soar If Rates Fall to 3%
Investors love dividend stocks, especially the blue-chip variety, because they offer a significant passive income stream and have massive total return potential.
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know
Recently, Zacks.com users have been paying close attention to Bristol Myers (BMY). This makes it worthwhile to examine what the stock has in store.
Bristol-Myers Squibb: Way Too Cheap At 7x P/E
Bristol-Myers Squibb is a compelling value and income opportunity, trading near 52-week lows with a 5.4% dividend yield and low forward P/E. BMY's growth portfolio, led by Opdivo, Reblozyl, and Breyanzi, is offsetting legacy drug declines, supported by strong Q3 results and robust pipeline catalysts. Disciplined cost management, an A credit rating, and ample free cash flow reinforce BMY's profitability and ability to fund dividends and R&D.
Bristol-Myers Squibb Company (BMY) Q3 2025 Earnings Call Transcript
Bristol-Myers Squibb Company ( BMY ) Q3 2025 Earnings Call October 30, 2025 8:00 AM EDT Company Participants Chuck Triano Christopher Boerner - CEO & Chairman David Elkins - Executive VP & CFO Cristian Massacesi - Executive VP, Chief Medical Officer & Head of Development Adam Lenkowsky - Executive VP & Chief Commercialization Officer Conference Call Participants Christopher Schott - JPMorgan Chase & Co, Research Division Geoffrey Meacham - Citigroup Inc., Research Division Evan Seigerman - BMO Capital Markets Equity Research David Amsellem - Piper Sandler & Co., Research Division Asad Haider - Goldman Sachs Group, Inc., Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Timothy Anderson - BofA Securities, Research Division Luisa Hector - Joh. Berenberg, Gossler & Co. KG, Research Division David Risinger - Leerink Partners LLC, Research Division Carter Gould - Cantor Fitzgerald & Co., Research Division Terence Flynn - Morgan Stanley, Research Division Courtney Breen - Sanford C.
Bristol-Myers Squibb Q3 Earnings Review: Despite Today's Gains, I See Trouble Ahead
Bristol-Myers Squibb Company's Q3 earnings are out - beating analyst's estimates - and for once, stock is buoyant (in trading so far today). BMY faces significant challenges as major drugs lose patent protection, leading to revenue declines despite a strong dividend yield. Recent acquisitions and new product launches have underperformed versus management's ambitious targets, raising concerns about BMY's growth prospects through 2030.
